Phreesia, Inc.

Equities

PHR

US71944F1066

Software

Market Closed - Nyse 04:00:02 2024-04-22 pm EDT 5-day change 1st Jan Change
22.41 USD +3.27% Intraday chart for Phreesia, Inc. -1.49% -3.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Phreesia Insider Sold Shares Worth $610,684, According to a Recent SEC Filing MT
JMP Securities Raises Price Target on Phreesia to $30 From $28, Maintains Market Outperform Rating MT
Phreesia Names Jack Callahan as Chief Technology Officer MT
Phreesia Appoints Jack Callahan as Chief Technology Officer CI
Baird Adjusts Price Target on Phreesia to $31 From $30, Maintains Outperform Rating MT
Raymond James Raises Phreesia's Price Target to $30 From $25, Maintains Outperform Rating MT
Canaccord Genuity Adjusts Price Target on Phreesia to $37 From $36, Maintains Buy Rating MT
RBC Raises Price Target on Phreesia to $23 From $17, Cites 'Encouraging Progress Toward Profitability,' Keeps Sector Perform Rating MT
Transcript : Phreesia, Inc., Q4 2024 Earnings Call, Mar 14, 2024
Phreesia Fiscal Q4 Net Loss Narrows, Revenue Increases; FY 2025 Revenue Outlook Maintained; Shares Rise After Hours MT
Phreesia Guides For FY 2025 Revenue of $424-$434 Million, vs CIQ Analyst Consensus of $428 Million MT
Earnings Flash (PHR) PHREESIA Posts Q4 Revenue $95M, vs. Street Est of $93.5M MT
Phreesia, Inc. Reports Earnings Results for the Fourth Quarter Ended January 31, 2024 CI
Phreesia, Inc. Reports Earnings Results for the Full Year Ended January 31, 2024 CI
Truist Securities Initiates Phreesia at Buy Rating With $35 Price Target MT
Phreesia Insider Sold Shares Worth $1,630,138, According to a Recent SEC Filing MT
Phreesia Insider Sold Shares Worth $1,046,093, According to a Recent SEC Filing MT
Phreesia Insider Sold Shares Worth $796,441, According to a Recent SEC Filing MT
Phreesia Insider Sold Shares Worth $458,552, According to a Recent SEC Filing MT
Phreesia Insider Sold Shares Worth $264,468, According to a Recent SEC Filing MT
Transcript : Phreesia, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:45 AM
Barclays Starts Phreesia With Overweight Rating, $29 Price Target MT
KeyBanc Adjusts Phreesia's PT to $30 From $40, Maintains Overweight Rating MT
Raymond James Adjusts Price Target on Phreesia to $25 From $30, Keeps Outperform Rating MT
Phreesia Shares Jump After Better-Than-Expected Fiscal Q3 Results MT
Chart Phreesia, Inc.
More charts
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. The Company also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
22.41 USD
Average target price
30.12 USD
Spread / Average Target
+34.43%
Consensus
  1. Stock Market
  2. Equities
  3. PHR Stock
  4. News Phreesia, Inc.
  5. Phreesia : Fiscal Q1 Loss Widens, Revenue Increases; Raises Fiscal 2022 Revenue Guidance